The vaccine, Tuohy tells Verywell, essentially works by nipping tumor development in the bud.
Most triple-negative breast cancers express alpha-lactalbumin," Tuohy says.
He describes the vaccine mechanism as simply taking advantage of this mistake.
PhotoAlto/Michele Constantini / Getty Images
What Happens Next?
The FDAs approval clears the way for the Cleveland Clinic to start Phase I clinical trials of the vaccine.
But it is hard to know exactly when the results might arrive.
My team takes [it] one day at a time," Tuohy says.
We hope to finish Phase I trials within two years after starting them."
He adds that he has “no idea when the vaccine might become widely available.
The preliminary results of several animal studies conducted by the clinic have been promising.
Kaumaya and his research team are working on several breast cancer treatment vaccines of their own.
Thats not to say, however, that it is a miracle cure for the disease.
“And to me, what is most important at this stage is the inclusion of checkpoint inhibitors.
Jordan, J.FDA clears way for Cleveland Clinics groundbreaking breast cancer vaccine.
American Cancer Society.Triple-negative breast cancer.
BioSpace.Anixa Biosciences and Cleveland Clinic file IND tool for breast cancer vaccine.
American Cancer Society.Cancer vaccines and their side effects.
2019;25(12):3495-3507. doi:10.1158/1078-0432.CCR-18-3997
